{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:30:44Z","timestamp":1792888244676,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ijrobp.2021.06.037","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:49:32Z","timestamp":1635184172000},"page":"75-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials"],"prefix":"10.1016","volume":"112","author":[{"given":"Jonathan E.","family":"Leeman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Bredfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent W.","family":"Mouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony V.","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Orio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.06.037_bib0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultrahypofractionated versus conventionally fractionated radiation therapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomized, noninferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0002","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.ijrobp.2020.07.836","article-title":"Patient-reported outcomes in NRG Oncology\/RTOG 0938, a randomized phase II study evaluating 2 ultrahypofractionated regimens (UHR) for prostate cancer (CaP)","volume":"108","author":"Lukka","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0003","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","article-title":"Stereotactic body radiation therapy versus intensity modulated radiation therapy for prostate cancer: Comparison of toxicity","volume":"32","author":"Yu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0004","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2014.06.031","article-title":"Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: Implications for establishing new dose constraints for treatment planning","volume":"90","author":"Hathout","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0005","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.brachy.2020.06.011","article-title":"Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy","volume":"19","author":"Boyce-Fappiano","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijrobp.2007.12.052","article-title":"Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy","volume":"72","author":"Thomas","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0007","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1002\/cam4.2966","article-title":"Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiation therapy, a randomized phase II trial: 18 months follow-up results","volume":"9","author":"Zilli","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0008","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-Year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0011","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0012","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate cancer: Early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0013","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00066-018-1338-7","article-title":"Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer","volume":"195","author":"Alongi","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0014","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/COC.0000000000000721","article-title":"Stereotactic body radiation therapy for intermediate-risk prostate cancer with VMAT and real-time electromagnetic tracking: A phase II study","volume":"43","author":"D'Agostino","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0015","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0016","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","article-title":"Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Seymour","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0017","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.prro.2016.07.004","article-title":"Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijrobp.2020.09.054","article-title":"Prostate stereotactic body radiation therapy: An overview of toxicity and dose response","volume":"110","author":"Wang","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0019","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/mp.12830","article-title":"Changes in prostate orientation due to removal of a Foley catheter","volume":"45","author":"Litzenberg","year":"2018","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2021.06.037_bib0020","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/j.prro.2019.06.009","article-title":"Comparison of motion-insensitive T2-weighted MRI pulse sequences for visualization of the prostatic urethra during MR simulation","volume":"9","author":"Zakian","year":"2019","journal-title":"Pract Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621008440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301621008440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:54:59Z","timestamp":1759744499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301621008440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0360301621008440"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.037","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Dose to the Intraprostatic Urethra Correlates Strongly With Urinary Toxicity After Prostate Stereotactic Body Radiation Therapy: A Combined Analysis of 23 Prospective Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}